{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:43:54Z","timestamp":1789191834586,"version":"build-2803163510"},"reference-count":84,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["INQUIRY"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for managing type 2 diabetes and obesity. As their clinical applications expand, interest in their safety and adverse effects has grown. This study provides a comprehensive bibliometric analysis of global research trends, collaboration patterns, and thematic evolution on GLP-1RA-related adverse effects from 2006 to 2025. This study is a bibliometric analysis. Data were extracted from the Scopus database and analyzed using Bibliometrix (R package) and VOS viewer. Indicators assessed included publication and citation metrics, institutional productivity, and keyword co-occurrence and mapping. Correlations were evaluated using Pearson and Spearman tests, and the Durbin\u2013Watson statistic was applied to assess the independence of residuals. A total of 1075 articles published in 389 journals were identified, authored by 6068 researchers across 85 countries. The annual growth rate was 32.06%, with no single-author papers and 34.23% international co-authorship, indicating strong global collaboration. The United States (30.5%), the United Kingdom (10.6%), and Denmark (7.8%) led in publication output and total citations. Institutional analysis identified Novo Nordisk A\/S (60 papers, 11\u2009207 citations) and Eli Lilly &amp; Co. (45 papers, 9948 citations) as the most influential contributors. Diabetes, Obesity and Metabolism published the most articles (n\u2009=\u2009106), followed by Diabetes Care and The Lancet Diabetes &amp; Endocrinology. Significant correlations were found between article count and h-index (\n                    <jats:italic toggle=\"yes\">r<\/jats:italic>\n                    \u2009=\u2009.677,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009&lt;\u2009.001) and total citations (\n                    <jats:italic toggle=\"yes\">r<\/jats:italic>\n                    \u2009=\u2009.779,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009&lt;\u2009.001). Keyword analysis revealed 2 main thematic clusters-one pharmacological (drug safety, efficacy, liraglutide, semaglutide) and 1 clinical (human, male, female, adult)\u2014with an emerging focus on population-specific safety since 2021. Research on GLP-1RA-related adverse effects has expanded rapidly, shaped by strong international collaboration and industry-academic partnerships. Future efforts should prioritize balanced global participation, real-world safety data, and mechanistic insights to inform clinical practice and pharmacovigilance.\n                  <\/jats:p>","DOI":"10.1177\/00469580261441498","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:03:22Z","timestamp":1777118602000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis"],"prefix":"10.1177","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1157-2739","authenticated-orcid":false,"given":"Riad Mohammed","family":"Abdelrahman","sequence":"first","affiliation":[{"name":"National University of Sudan, Khartoum, Sudan"},{"name":"National Ribat University, Khartoum, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha Hussein","family":"Musa","sequence":"additional","affiliation":[{"name":"Libyan International Medical University, Benghazi, Libya"},{"name":"Darfur University College, Nyala, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail Adam","family":"Arbab","sequence":"additional","affiliation":[{"name":"Libyan International Medical University, Benghazi, Libya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltieb Omer","family":"Ahmed","sequence":"additional","affiliation":[{"name":"International University of Africa, Khartoum, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar Ibrahim","family":"Gasmallah","sequence":"additional","affiliation":[{"name":"University of Bahri, Khartoum, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Jalal","sequence":"additional","affiliation":[{"name":"Karary University, Khartoum, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafaa Ramadan","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Libyan International Medical University, Benghazi, Libya"},{"name":"Assiut University, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Hamid","family":"Fadul","sequence":"additional","affiliation":[{"name":"International University of Africa, Khartoum, Sudan"},{"name":"Sudan Medical Specialization Board, Khartoum, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2023.1085799"},{"key":"e_1_3_3_4_2","unstructured":"Drug approval package: Byetta (Exenatide) NDA #021773. 2005. Accessed April 12 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021773_byettatoc.cfm"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.11.034"},{"key":"e_1_3_3_6_2","unstructured":"FDA. FDA approves weight management drug for patients aged 12 and older. FDA. 2021. Accessed April 9 2025. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-weight-management-drug-patients-aged-12-and-older"},{"key":"e_1_3_3_7_2","unstructured":"FDA. Update on FDA\u2019s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. FDA. 2024. Accessed April 12 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type"},{"key":"e_1_3_3_8_2","unstructured":"Dorrell M. Rx History: The rise of GLP-1s. Innovative Rx Strategies. 2024. Accessed April 10 2025. https:\/\/innovativerxstrategies.com\/rx-history-glp1s\/"},{"key":"e_1_3_3_9_2","unstructured":"Leon N Lacoursiere R Yarosh D Patel RS. Lixisenatide (Adlyxin): a once-daily incretin mimetic injection for type-2 diabetes. Pharm Ther. 2017;42(11):676. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5642155\/ Accessed April 9 2025."},{"key":"e_1_3_3_10_2","unstructured":"Stewart J. Ozempic (semaglutide) FDA approval history. Drugs.com. 2026. Accessed April 12 2025. https:\/\/www.drugs.com\/history\/ozempic.html"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/OBR.12839"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019889064"},{"key":"e_1_3_3_14_2","unstructured":"FDA. FDA approves new drug treatment for chronic weight management first since 2014. 2021. Accessed April 12 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014"},{"key":"e_1_3_3_15_2","unstructured":"Eli Lilly and Company. Trulicity & weight loss HCP Trulicity (dulaglutide). 2024. Accessed April 12 2025. https:\/\/trulicity.lilly.com\/hcp\/efficacy-weight\/weight-loss-dosing"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77089"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924000531"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae176"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1513641"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.12.014"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2021.05.009"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2023.1214334"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00970-2"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","unstructured":"Dos Santos BNC Castro RS. Adverse effects of GLP-1 analogues: A systematic review. Res Soc Develop. 2025;14: e2914147981. https:\/\/rsdjournal.org\/rsd\/article\/view\/47981","DOI":"10.33448\/rsd-v14i1.47981"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0046"},{"key":"e_1_3_3_26_2","unstructured":"U.S. Food and Drug Administration. FDA\u2019s concerns with unapproved GLP-1 drugs used for weight loss. 2025. Accessed October 5 2025. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.4292\/wjgpt.v16.i3.107148"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.06.003"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2025.0242"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0003"},{"key":"e_1_3_3_32_2","unstructured":"American Medical Association. New FDA warning label for Ozempic and Wegovy\u2014plus how and where to get a free COVID vaccine. 2025. Accessed April 10 2025. https:\/\/www.ama-assn.org\/delivering-care\/public-health\/new-fda-warning-label-ozempic-and-wegovy-plus-how-and-where-get-free"},{"key":"e_1_3_3_33_2","unstructured":"U.S. Food and Drug Administration. Drug safety-related labeling changes (SrLC). 2025. Accessed April 10 2025. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/safetylabelingchanges\/index.cfm?event=searchResult.page"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/11795514211051697"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-4162"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1603827"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1607141"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05962-z"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15872"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6507.20.03219-8"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2366"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.2337\/DC13-2983"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.02.024"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.r1606"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.0338"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13725"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02753-6"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13172"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-025-01859-6"},{"key":"e_1_3_3_54_2","unstructured":"EQUATOR Network. Preliminary guideline for reporting bibliometric reviews of the biomedical literature (BIBLIO): a minimum requirements. EQUATOR Network. 2026. Accessed February 25 2026. https:\/\/www.equator-network.org\/reporting-guidelines\/preliminary-guideline-for-reporting-bibliometric-reviews-of-the-biomedical-literature-biblio-a-minimum-requirements\/"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.JOI.2017.08.007"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/S11192-009-0146-3"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/DMRR.2810"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12982"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/S11192-013-1121-6"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJOR.2016.07.058"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-006-0144-7"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","unstructured":"Moed HF. Citation analysis in research evaluation. Springer;2005. Vol. 9. doi:10.1007\/1-4020-3714-7","DOI":"10.1007\/1-4020-3714-7"},{"key":"e_1_3_3_63_2","first-page":"90","author":"Belsley DA","year":"1980","unstructured":"Belsley DA, Kuh E, Welsch RE. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. Wiley; 1980:90-110","journal-title":"Regression Diagnostics: Identifying Influential Data and Sources of Collinearity"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.5117\/2006.019.003.007"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.JOI.2018.05.001"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.JOI.2024.101565"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.5794\/jjoms.69.409"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/ASI.23728"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1108\/00220410810844150"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2014.03.005"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.11.002"},{"key":"e_1_3_3_73_2","unstructured":"SciTechnol. Obesity and type 2 diabetes: pathophysiology and therapeutic interventions. SciTechnol. 2025. Accessed October 12 2025. https:\/\/www.scitechnol.com\/peer-review\/obesity-and-type-2-diabetes-pathophysiology-and-therapeutic-interventions-9odP.php?article_id=23022"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.766125"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0182"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620953935"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.669509"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.OBMED.2025.100640"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042257"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103021"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.004"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01722-x"},{"key":"e_1_3_3_84_2","unstructured":"American Diabetes Association Institute of Learning. Real-world evidence for clinical decision making in diabetes: opportunities and challenges. American Diabetes Association; 2023. Accessed October 12 2025. https:\/\/professionaleducation.diabetes.org\/Listing\/Real-World-Evidence-for-Clinical-Decision-Making-in-Diabetes-Opportunities-and-Challenges-18093"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001184"}],"container-title":["INQUIRY: The Journal of Health Care Organization, Provision, and Financing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00469580261441498","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00469580261441498","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00469580261441498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:11:29Z","timestamp":1777461089000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00469580261441498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":84,"alternative-id":["10.1177\/00469580261441498"],"URL":"https:\/\/doi.org\/10.1177\/00469580261441498","relation":{},"ISSN":["0046-9580","1945-7243"],"issn-type":[{"value":"0046-9580","type":"print"},{"value":"1945-7243","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"00469580261441498"}}